Sohrab Shah, PhD

Chief of Computational Oncology; Nicholls-Biondi Chair in Computational Oncology
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Sohrab Shah, PhD

Chief of Computational Oncology; Nicholls-Biondi Chair in Computational Oncology
Share
Share
Sohrab Shah

Office Phone

646-608-7558

Email

[email protected]

URL

View Sohrab Shah’s Lab

Sohrab Shah is the Chief of Computational Oncology in the Department of Epidemiology and Biostatistics. Dr. Shah received a PhD in computer science from the University of British Columbia in 2008 and developed his research program in computational biology at BC Cancer Agency and the University of British Columbia starting in 2010. His research focuses on developing and using computational methods to understand cancer evolution and treatment response. This encompasses advanced machine learning and Bayesian statistical methods to analyze and interpret large-scale datasets in cancer research. At MSK, Dr. Shah is building new and innovative capacity in computational methods across the spectrum of data-intensive research activity. This includes multimodal data integration such as genomics and imaging, high-resolution single-cell genomics, and transcriptomics. His translational focus lies in breast cancer and ovarian cancer, in which he has pioneered discovery of prognostic mutational signatures and large-scale studies of mutational landscapes and evolution of these cancers. Dr. Shah is a former Canada Research Chair, is a Komen Scholar, and holds the Nicholls-Biondi Endowed Chair in Computational Oncology at MSK.

Publications

  1. Ceglia N, Sethna Z, Freeman SS, … Shah SP, McPherson A. Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector. Nat Commun. 2023 14(1):4400. PMCID: PMC10359421.
  2. Funnell T*, O’Flanagan C*, Williams M*, … Shah SP, Aparicio S. Single cell genomic variation induced by mutational processes in cancer. Nature 2022; 612(7938):106-115. PMCID: PMC9712114.
  3. Vázquez-García, I., Uhlitz, F., Ceglia, N. … Shah SP. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 2022; 612(7941):778-786. PMCID: PMC9771812.
  4. Boehm KM, Aherne EA, Ellenson L, … Shah SP. Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nat Cancer. 2022 (6):723-733. PMCID: PMC9239907.
  5. Vanguri RS, Luo J, Aukerman AT, … Shah SP. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022 (10):1151-1164. PMCID: PMC9586871.
  6. Salehi S, Kabeer F, Ceglia N… Shah SP. Clonal fitness inferred from timeseries modeling of single cell cancer genomes. Nature 2021;595(7868):585–590. PMCID: PMC8396073.
  7. Laks E, Zahn H, Lai D, McPherson A, Steif A,… Shah SP, Aparicio S. Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing Cell. 2019;179(5):1207-1221.e22. PMCID: PMC6912164.
  8. Funnell T, Zhang AW, Grewal D, … Shah SP. Integrated structural variation and point mutation signatures in cancer genomes using correlated topic models. PLoS Comput Biol. 2019;15(2):e1006799. PMCID: PMC6402697.
  9. Zhang AW… Shah SP. Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling. Nat Methods. 2019;16(10):1007-15. PMCID: PMC7485597
  10. Campbell KR, Steif A, Laks E… Shah SP. clonealign: statistical integration of independent single-cell RNA and DNA sequencing data from human cancers. Genome Biol. 2019;20(1):54. doi: 10.1186/s13059-019-1645-z. PMCID: PMC6417140.

View a complete listing of Sohrab Shah’s publications

My Pages

My Videos

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sohrab Shah discloses the following relationships and financial interests:

  • AstraZeneca UK Limited
    Professional Services and Activities (Uncompensated)
  • Bristol-Myers Squibb
    Professional Services and Activities (Uncompensated)
  • Imagia Canexia Health Inc.
    Equity

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures
Related topics: